Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
314 stopped studies mapped to Kidney Carcinoma and descendants · 86% state a reason
Over the 314 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04680416 | Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to… | — | withdrawn | Dec 23, 2020 | TScan Therapeutics, Inc. | Lack of patient samples | Other (stated, no rule matched) |
| NCT01649180 | NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant…(PrE0801) | Phase 2 | terminated | Jul 25, 2012 | PrECOG, LLC. | Closed due to prolonged enrollment timelines | Enrollment / accrual |
| NCT01147536 | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants… | Phase 2 | terminated | Jun 22, 2010 | Agenus Inc. | Sponsor's business decision | Sponsor / business decision |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma,… | Phase 1 / Phase 2 | terminated | Oct 21, 2015 | Dana-Farber Cancer Institute | The study closed primarily due to weak accrual, as well as study design limitations. | Enrollment / accrual |
| NCT01253668 | Brivanib Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Dec 3, 2010 | Abramson Cancer Center at Penn Medicine | In November 2012, this study was permanently closed to new accrual at the request of the drug… | Drug supply |
| NCT03189186 | Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by… | Phase 1 | withdrawn | Jun 16, 2017 | University of California, Irvine | This study was closed due to extremely low accrual, as well as a change in care when using the… | Enrollment / accrual |
| NCT00324740 | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer | Phase 1 / Phase 2 | terminated | May 11, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02495103 | Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney… | Phase 1 / Phase 2 | terminated | Jul 13, 2015 | National Cancer Institute (NCI) | Vandetanib is no longer available as Sanofi has decided not to provide additional drug. All… | Other (stated, no rule matched) |
| NCT02853162 | Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body…(ARREST) | Phase 2 | terminated | Aug 2, 2016 | UMC Utrecht | Slow inclusion | Other (stated, no rule matched) |
| NCT04609800 | Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic…(CAROLINE) | — | withdrawn | Oct 30, 2020 | Ipsen | Unfavorable opinion of IRB/IEC | Other (stated, no rule matched) |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | Phase 1 | terminated | Oct 27, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02131376 | Investigating a Novel Modifiable Factor Affecting Renal Function After Partial… | N/A | terminated | May 6, 2014 | Indiana University | slow accrual, interim analysis showed no statistical significance | Efficacy / futility |
| NCT02071719 | Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in… | — | terminated | Feb 26, 2014 | M. Labots | not stated | Not stated |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer…(DOMINATION) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT01673386 | A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With…(TAURUS) | Phase 2 | terminated | Aug 28, 2012 | AVEO Pharmaceuticals, Inc. | Sponsor | Other (stated, no rule matched) |
| NCT02595918 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | Phase 1 | terminated | Nov 4, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal… | Phase 1 / Phase 2 | terminated | Mar 7, 2013 | Tracon Pharmaceuticals Inc. | The study did not meet endpoint. | Other (stated, no rule matched) |
| NCT03598816 | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for…(PIVOT-RCC) | Phase 2 | withdrawn | Jul 26, 2018 | Washington University School of Medicine | FDA Contingencies unresolved | Other (stated, no rule matched) |
| NCT04260360 | Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma | Phase 1 | withdrawn | Feb 7, 2020 | NanOlogy, LLC | Not initiated | Other (stated, no rule matched) |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell… | Phase 1 | terminated | Aug 8, 2014 | Merck Sharp & Dohme LLC | Terminated early due to low enrollment | Enrollment / accrual |
| NCT02170389 | Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer | N/A | terminated | Jun 23, 2014 | Roswell Park Cancer Institute | sponsor having financial difficulties | Funding |
| NCT00953446 | Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of… | N/A | terminated | Aug 6, 2009 | Beth Israel Deaconess Medical Center | not stated | Not stated |
| NCT02089334 | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal… | Phase 1 / Phase 2 | terminated | Mar 17, 2014 | Rexahn Pharmaceuticals, Inc. | not stated | Not stated |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid… | Phase 1 | terminated | Nov 17, 2017 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell… | Phase 1 | terminated | Jul 20, 2016 | Celldex Therapeutics | Development of CDX-014 discontinued | Other (stated, no rule matched) |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | Phase 1 / Phase 2 | withdrawn | Apr 25, 2019 | HealthPartners Institute | funding issues | Funding |
| NCT00854022 | Genetic Susceptibility to Kidney Cancer | — | terminated | Mar 2, 2009 | Baylor College of Medicine | Funding ended | Funding |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT03943771 | Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to…(R3DP-A) | N/A | withdrawn | May 9, 2019 | University Hospital, Bordeaux | Schedule issue | Other (stated, no rule matched) |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating… | Phase 2 | withdrawn | May 2, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT03692338 | INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or…(INTERVAL) | N/A | terminated | Oct 2, 2018 | Duke University | Poor accrual | Enrollment / accrual |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy… | Phase 1 / Phase 2 | terminated | Sep 11, 2009 | Celgene | MTD determined sub-optimal as efficacious treatment for renal cell carcinoma. | Other (stated, no rule matched) |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | Phase 2 | terminated | May 2, 2008 | National Cancer Institute (NCI) | A more highly selected protocol with ESO TCR opened for pts with melanoma | Other (stated, no rule matched) |
| NCT02795819 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | Phase 1 | terminated | Jun 10, 2016 | Virginia Commonwealth University | Study drug no longer being clinically developed by manufacturer | Drug supply |
| NCT01239342 | Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | Phase 2 | terminated | Nov 11, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01545817 | Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma(CATChEz) | Phase 2 | terminated | Mar 7, 2012 | Novartis Pharmaceuticals | As the therapeutic landscape in renal cell carcinoma is changing, it has become apparent that… | Other (stated, no rule matched) |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma… | Phase 1 / Phase 2 | terminated | May 19, 2015 | Fox Chase Cancer Center | IRB study closure facilitated by Investigator | Investigator |
| NCT01599754 | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients(ATLAS) | Phase 3 | terminated | May 16, 2012 | SFJ Pharma Ltd. II | Primary endpoint did not reach statistical significance | Other (stated, no rule matched) |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | N/A | withdrawn | Jan 24, 2018 | University of Southern California | No accrual | Enrollment / accrual |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal… | Phase 1 / Phase 2 | terminated | May 9, 2006 | AHS Cancer Control Alberta | Retirement of former Qualified Investigator and lack of resources to complete study. | Investigator |
| NCT01391130 | A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Jul 11, 2011 | Eli Lilly and Company | Study Terminated due to Insufficient Efficacy | Efficacy / futility |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 2, 2016 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | Phase 1 / Phase 2 | withdrawn | Apr 13, 2017 | William Grosh, MD | funding was withdrawn | Funding |
| NCT00538772 | An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell… | — | withdrawn | Oct 3, 2007 | Kim Chi | not stated | Not stated |
| NCT02428335 | Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib | — | withdrawn | Apr 28, 2015 | AHS Cancer Control Alberta | Insufficient financial resources to conduct research and complete trial. | Funding |
| NCT03528057 | Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy | N/A | withdrawn | May 17, 2018 | Northwestern University | Difficulty recruiting participants. | Enrollment / accrual |
| NCT02005614 | A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI… | N/A | terminated | Dec 9, 2013 | Yale University | Unable to recruit patients. | Enrollment / accrual |
| NCT03185182 | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma(RCCSCAN) | Phase 2 | terminated | Jun 14, 2017 | Region Skane | Due to "early stopping rule" as defined in the study protocol | Other (stated, no rule matched) |
| NCT01195649 | Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or… | — | terminated | Sep 6, 2010 | Bayer | not stated | Not stated |
| NCT00727532 | Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | N/A | terminated | Aug 4, 2008 | Northwestern University | Low Accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 25, 2021source: clinicaltrials